Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Vyne Therapeutics Inc. Clear all
Completed Phase 2 Interventional

VPD-737 for Treatment of Chronic Pruritus

NCT01951274
View directory record Official record
Conditions
Chronic Pruritus
Interventions
VPD-737, Placebo
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Fremont, California • Lomita, California • Redwood City, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 4 Interventional

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

NCT04940767
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Isotretinoin, Amzeeq 4% Topical Foam
Drug
Lead sponsor
Edward Lain, MD
Network
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Dripping Springs, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 5, 2026, 8:29 AM EDT
Terminated Phase 2 Interventional

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

NCT02975271
View directory record Official record
Conditions
Pruritus, Burns
Interventions
Serlopitant, Placebo
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

NCT03841331
View directory record Official record
Conditions
Pruritus
Interventions
5 mg Serlopitant Tablets, Matching Placebo Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Hot Springs, Arkansas • Bakersfield, California • Fremont, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

NCT04927572
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FMX114, Vehicle
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815280
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Glendale, Arizona • Rogers, Arkansas • Oceanside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

NCT02654483
View directory record Official record
Conditions
Epidermolysis Bullosa, Pruritus
Interventions
VPD-737, Placebo
Drug · Other
Lead sponsor
Jean Yuh Tang
Other
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815267
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Birmingham, Alabama • Fremont, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

NCT03836001
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Serlopitant Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

NCT03343639
View directory record Official record
Conditions
Pruritus, Psoriasis
Interventions
5 mg Serlopitant Tablets, Matching Placebo Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
39
States / cities
Bryant, Arkansas • Beverly Hills, California • Fremont, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

NCT04104685
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam
Combination Product · Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

NCT06493578
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
VYN201 Gel, Vehicle Gel
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Results available

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

NCT03743038
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX101 vehicle, Hydro-alcohol solution
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

NCT02094716
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Foam 4%, Permethrin Foam 5%, Vehicle Foam
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Months and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Fremont, California • Los Angeles, California • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

NCT03271021
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX101, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
1,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
98
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 5, 2026, 8:29 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

NCT03540160
View directory record Official record
Conditions
Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions
5 mg Serlopitant Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

NCT02975206
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Serlopitant High Dose, Placebo Oral Tablet, Serlopitant Low Dose
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
13 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 44 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT03142451
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
54
States / cities
Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

NCT03546816
View directory record Official record
Conditions
Pruritus, Prurigo Nodularis
Interventions
5mg Serlopitant Tablets, Placebo Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
49
States / cities
Birmingham, Alabama • Rogers, Arkansas • Fremont, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03276936
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
FMX103 1.5%
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
79
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 5, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

NCT03282591
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
5 mg Serlopitant Tablets, Matching Placebo Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
29
States / cities
Los Angeles, California • Mission Viejo, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 5, 2026, 8:29 AM EDT